<p>A monocentric retrospective real-world study
from North Poland of dupilumab in adults and paediatric
patients with atopic dermatitis: efficacy, safety,
and dupilumab-associated hypereosinophilia</p>

Weronika Zysk; Magdalena Trzeciak; Aleksandra Wilkowska; Roman Nowicki

doi:10.5114/ada.2026.162034

A monocentric retrospective real-world study from North Poland of dupilumab in adults and paediatric patients with atopic dermatitis: efficacy, safety, and dupilumab-associated hypereosinophilia

Weronika Zysk ^{1, 2}

,

Magdalena Trzeciak ^{1, 2}

,

Aleksandra Wilkowska ²

,

Roman J. Nowicki ^{1, 2}

Department of Dermatology, Venereology and Allergology, Faculty of Medicine, Medical University of Gdansk, Poland
Department of Dermatology, Venereology and Allergology, University Clinical Centre, Gdansk, Poland

Adv
Dermatol Allergol

DOI: https://doi.org/10.5114/ada.2026.162034

Online publish date: 2026/05/27

View full text

AMA

Zysk W, Trzeciak M, Wilkowska A, Nowicki RJ. A monocentric retrospective real-world study from North Poland of dupilumab in adults and paediatric patients with atopic dermatitis: efficacy, safety, and dupilumab-associated hypereosinophilia. Postępy Dermatologii i Alergologii/Advances in Dermatology and Allergology. 2026. doi:10.5114/ada.2026.162034.

APA

Zysk, W., Trzeciak, M., Wilkowska, A., & Nowicki, R. J. (2026). A monocentric retrospective real-world study from North Poland of dupilumab in adults and paediatric patients with atopic dermatitis: efficacy, safety, and dupilumab-associated hypereosinophilia. Postępy Dermatologii i Alergologii/Advances in Dermatology and Allergology. https://doi.org/10.5114/ada.2026.162034

Chicago

Zysk, Weronika, Magdalena Trzeciak, Aleksandra Wilkowska, and Roman J Nowicki. 2026. "A monocentric retrospective real-world study from North Poland of dupilumab in adults and paediatric patients with atopic dermatitis: efficacy, safety, and dupilumab-associated hypereosinophilia". Postępy Dermatologii i Alergologii/Advances in Dermatology and Allergology. doi:10.5114/ada.2026.162034.

Harvard

Zysk, W., Trzeciak, M., Wilkowska, A., and Nowicki, R. (2026). A monocentric retrospective real-world study from North Poland of dupilumab in adults and paediatric patients with atopic dermatitis: efficacy, safety, and dupilumab-associated hypereosinophilia. Postępy Dermatologii i Alergologii/Advances in Dermatology and Allergology. https://doi.org/10.5114/ada.2026.162034

MLA

Zysk, Weronika et al. "A monocentric retrospective real-world study from North Poland of dupilumab in adults and paediatric patients with atopic dermatitis: efficacy, safety, and dupilumab-associated hypereosinophilia." Postępy Dermatologii i Alergologii/Advances in Dermatology and Allergology, 2026. doi:10.5114/ada.2026.162034.

Vancouver

Zysk W, Trzeciak M, Wilkowska A, Nowicki R. A monocentric retrospective real-world study from North Poland of dupilumab in adults and paediatric patients with atopic dermatitis: efficacy, safety, and dupilumab-associated hypereosinophilia. Postępy Dermatologii i Alergologii/Advances in Dermatology and Allergology. 2026. doi:10.5114/ada.2026.162034.

Introduction

Long-term real-life data on the efficacy of dupilumab in atopic dermatitis (AD) patients, especially within the paediatric population, are limited.

Aim

We aimed to evaluate in real life the effectiveness and safety of dupilumab in the treatment of adults and paediatric patients (6–17 years) with a special focus on the (hyper)eosinophilia trend during treatment.

Material and methods

A monocentric retrospective study was conducted at the Department of Dermatology, Venereology, and Allergology in Gdansk, Poland.

Results

A total of 70 patients were included, comprising 44 adults and 26 paediatric patients. In paediatric patients, Eczema Area and Severity Index (EASI) decreased by 86.65%, pruritus (P-NRS) by 72.40%, sleep disturbances (SD-NRS) by 73.44%, and Children’s Dermatology Life Quality Index (cDLQI) by 76.82% at week (W) 52. In adults, EASI decreased by 95.66%, P-NRS by 79.66%, SD-NRS by 92.12%, and Dermatology Life Quality Index (DLQI) by 87.54% at W104. Among the paediatric patients, 17 experienced (hyper)eosinophilia at baseline (17/25, 68.0%), and 22 experienced (hyper)eosinophilia during the treatment period (22/26, 84.62%). Among adults, 24 experienced (hyper)eosinophilia at baseline (24/44, 54.55%), and 35 experienced (hyper)eosinophilia during the treatment period (35/44, 79.55%). No one discontinued treatment due to hypereosinophilia.

Conclusions

Our results demonstrate that dupilumab is an effective and safe treatment for AD in both paediatric and adult populations in real-life settings, with significant and lasting improvements in disease severity and quality of life.

Keywords

atopic dermatitis, dupilumab, efficacy, safety, hypereosinophilia

Share

Indexed in

Integrated with

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications